The rationale for pulpotomy of primary molars is based on the assumption that inflammation is limited to the coronal portion of the dental pulp and that the radicular pulp has the potential to heal.
Since 1950, formocresol (FC) has been widely used as a pulp dressing material for pulpotomy of primary molars. However, many concerns have been raised about the potential mutagenicity and carcinogenicity of FC in humans and therefore alternative pulpotomy agents have been proposed.
In the present study, we suggest using 3Mixtatin, a combination of 3Mix (combination of metronidazole, minocycline, and ciprofloxacin ) and Simvastatin, as a pulpotomy material. This combination, 3Mixtatin, will be applied with the aim of suppressing bacteria, preventing the pulp inflammation and inducing hard tissue formation.
After local anesthesia, isolation and removing caries, following removal of the coronal pulp and hemostasis, the pulp stumps will be covered with 3Mixtatin in group B and Mineral trioxide aggregate ( MTA) in group C. In the control group, FC will be placed with a cotton pellet over the pulp stumps for 5 minutes and removed. The pulp stumps will then be covered by reinforcezinc oxide eugenol (ZOE) paste. All of the treated teeth will subsequently be restored with amalgam and radiography will be taken.
The teeth will be followed up 3 months after treatment. In follow up appointment, teeth will be evaluated radiographically and clinically with two examiners who are blind to the experiment.